Jacobs Levy Equity Management, Inc Apellis Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $50,017 - $65,440	903 Added 4.71%	20,057 $1.18 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $3.36 Million - $5.86 Million	-90,354 Reduced 82.51%	19,154 $1.15 Million
Q3 2023 Nov 16, 2023	BUY	$23.65 - $89.22 $2.59 Million - $9.77 Million	109,508 New	109,508 $4.17 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $11 Million - $16.8 Million	-310,594 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $6.24 Million - $9.98 Million	-203,047 Reduced 39.53%	310,594 $14.7 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $12.3 Million - $27.3 Million	390,616 Added 317.51%	513,641 $16.9 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $5.65 Million - $8.97 Million	-138,243 Reduced 52.91%	123,025 $7.78 Million
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $7.38 Million - $10.4 Million	180,887 Added 225.04%	261,268 $11.2 Million
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $1.23 Million - $2.28 Million	-39,862 Reduced 33.15%	80,381 $4.6 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $1.05 Million - $1.37 Million	40,731 Added 51.23%	120,243 $3.63 Million
Q2 2020 Aug 17, 2020	BUY	$24.8 - $38.49 $1.97 Million - $3.06 Million	79,512 New	79,512 $2.6 Million

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.